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Two travellers returning from South America were diagnosed with Andes hantavirus infection, the only member of the Hantaviridae 
family known to be transmitted from person to person. We describe the clinical course and therapeutic and infection control mea-
sures. While both patients showed high viral load (VL) and shedding over several months, 1 patient recovered within 1 week from 
severe respiratory illness that required noninvasive ventilation, whereas the second patient developed severe hantavirus cardiopul-
monary syndrome that required extracorporeal membrane oxygenation for 27 days. The clinical course in the latter patient was 
complicated by severe disseminated intravascular coagulopathy with diffuse hemorrhage that necessitated mass transfusions, as 
well as by multiple organ failure, including the need for renal replacement therapy. Results of VL in blood, respiratory secretions, 
and semen for the first 9 months of follow-up are reported. To our knowledge, these are the first cases of Andes hantavirus infection 
detected in Europe.
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CASE REPORTS
Patient 1
A previously healthy 55-year-old man presented to our emer-
gency department (ED) in early December 2016 with fever, 
chills, fatigue, and headaches. Together with his wife, he had 
trekked from Ecuador to Chile from September 2016 to 
November 2016. Activities also included camping and tak-
ing mud baths. Patient 1 first developed fever upon return to 
Switzerland, 7  days before seeking medical care. At presenta-
tion, hypotension (90/55  mm Hg), tachycardia (120 bpm), 
and fever (39°C) were noted. Blood tests revealed moderately 
elevated inflammatory markers (leucocytes, 7.3 G/L with 35% 
bands; C-reactive protein, 68  mg/L) and thrombocytopenia 
(48 G/L). Chest radiography showed mild perihilar pulmonary 
infiltrates. Malaria, dengue, human immunodeficiency virus 
infection, and common viral respiratory pathogens were ruled 
out. During the first 24 hours of admission, the patient devel-
oped marked prostration and respiratory distress that required 
noninvasive mechanical ventilation for 4  days. A  computed 
tomography (CT) scan of the chest confirmed bilateral pul-
monary infiltrates with pleural effusions. Based on the travel 
history, hantavirus infection was suspected by the infectious dis-
ease and tropical medicine consult service and later confirmed 
by reverse transcription polymerase chain reaction (RT-PCR) 
as well as by positive immunoglobulin (Ig) M and IgG serology 
to be Andes hantavirus (ANDV). Given the pronounced weak-
ness of the patient, he was transferred to a rehabilitation facility 
on day 8. Full recovery was achieved after another month.
Patient 2
The first patient’s previously healthy 54-year-old wife pre-
sented to our ED with unspecific symptoms 18 days after her 
husband’s admission. As she was in good clinical condition and 
vital signs were within normal range, the patient was discharged 
with the diagnosis of bronchitis. Serology and serum RT-PCR 
for ANDV had been negative 5  days earlier, taken after her 
husband’s diagnosis was established, to check for past asymp-
tomatic infection or for potential viral replication in the incu-
bation period. However, 21 days after her husband’s admission 
(day 1 for patient 2), she complained of extreme fatigue, myal-
gia, headache, and shortness of breath. Upon presentation, she 
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was febrile (38.6°C) with normal blood pressure, heart rate, and 
oxygen saturation at ambient air. Laboratory results (Table 1) 
revealed leukopenia (1.88 G/L) and thrombocytopenia (98 
G/L). Malaria and common causes of respiratory infections 
were excluded. Admitted for suspected ANDV infection, she 
deteriorated rapidly, requiring intubation and mechanical ven-
tilation for acute respiratory failure on day 2. Only a few hours 
later, the patient fulfilled fast entry criteria for extracorporeal 
membrane oxygenation (ECMO) due to severe acute cardiopul-
monary failure (PaO2/FiO2 ratio, 31), and peripheral veno-arte-
rial ECMO was installed (venous cannula in right femoral vein; 
arterial cannula in left femoral artery). On the same day, she also 
developed life-threatening diffuse hemorrhage with advanced 
coagulopathy and profound thrombocytopenia (nadir, 15 G/L 
on day 4), suggesting disseminated intravascular coagulation. 
During the next 3  days, she required mass transfusions of 
blood products: 62 packed red blood cell units, 24 thrombocyte 
concentrates, and 53 units of fresh frozen plasma, and over 4 
weeks a total of 102, 42, and 67 units, respectively (Figure 1). 
Hypoperfusion of the left leg due to the ECMO access made 
sternotomy for central ECMO cannulation necessary. Severe 
reperfusion injury and compartment syndrome of the left leg 
resulted in several vascular interventions and, ultimately, in 
through-knee amputation on day 9.  Moreover, compartment 
syndrome due to capillary leak necessitated multiple fascioto-
mies of the right leg and amputation of 3 toes. Five emergency 
interventions were required due to diffuse bleeding from the 
different ECMO insertion sites (mediastinum and groin) as well 
as from the left pulmonary lobe. Hemodiafiltration was started 
on day 4 for anuric renal failure. We administered ribavirin for 
13 days from day 3 onward and added corticosteroid therapy for 
pronounced capillary leak syndrome. The patient also received 
broad-spectrum antibiotics as empiric treatment due to severe 
sepsis and worsening respiratory failure. Later, in view of possi-
ble candidemia, anidulafungin was supplemented.
Cardiac function stabilized over the subsequent 2 weeks, 
whereas respiratory function remained compromised, with a 
chest CT showing carnification of both basal lung fields and left 
pleural effusion (Figure 2). Culture of purulent pleural effusions 
on day 12 revealed Aspergillus fumigatus, and anidulafungin 
was replaced with voriconazole. Ventilator-associated pneumo-
nia with Pseudomonas aeruginosa with increasingly resistant 
strains made combination antibiotic therapy necessary. ECMO 
was switched from venoarterial to venovenous cannulation on 
day 9. Because of intrathoracic compartment syndrome, closure 
of the thorax was only possible on day 15. In week 6, sternum 
infection with P. aeruginosa required several revisions and sec-
ondary closure with a rectus abdominis muscle flap. The patient 
was decannulated from ECMO on day 29. At 9  months after 
diagnosis, she still required positive pressure ventilation sup-
port all night and periodically during the day. Renal replace-
ment therapy was discontinued after 46  days. Due to further 
complications, the patient remained in acute care for 6 months 
before transfer to a rehabilitation center.
Table 1. Laboratory Results of Patient 2 From Day 3 (First Ambulatory Visit to Emergency Department) to Day 7 (One Week After Admission)
Laboratory Value Reference Range Day 3 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Creatinine (45–84 mmol/L) 64 66 64 66 162 128 NA NA
Estimated glomerular filtration rate according 
to Chronic Kidney Disease Epidemiology 
Collaboration
(>59 mL/min) >90 >90 >90 >90 31 41 NA NA
Urea (3.5–7.2 mmol/L) 3.7 NA 2.4 3.8 9.4 10.8 NA NA
C-reactive protein (<5 mg/L) <3 7 53 72 50 68 NA NA
Procalcitonin (<0.1 µg/L) NA NA NA NA 45.8 NA NA NA
Aspartate aminotransferase (<35 U/L) NA 24 158 151 1514 479 NA NA
Alanine aminotransferase (<35 U/L) NA 19 157 107 975 142 NA NA
Lactate (0.63–2.44 mmol/L) NA 0.8 NA 10.5 10.8 9.7 3.3 1.8
pH (arterial) (7.35–7.45) NA NA NA 7.15 7.16 7.3 7.43 7.45
Creatinine kinase (>170 U/L) 55 NA NA 102 213 9235 NA NA
Leukocytes (3.0–10.5 G/L) 3.15 2.02 2.37 19.1 7.19 8.27 7.44 7.3
Hemoglobin (121–154 g/L) 145 131 128 93 69 98 75 86
Hematocrit (0.36–0.44 L/L) 0.42 0.38 0.37 0.28 0.19 0.28 0.21 0.25
Platelets (150–450 G/L) 182 98 57 20 15 32 49 23
Neutrophils (1.6–7.4 G/L) NA 1.48 1.72 NA 4.63 4.26 4.72 5.8
Lymphocytes (1.1–3.5 G/L) NA 0.39 0.38 NA 1.11 1.08 0.1 0.73
INR <1 1.06 1.1 1.46 1.7 1.22 1.15 1.07
Activated partial thromboplastin time (25.0–36.0 sec) NA 42.1 45.2 79.9 86.8 63.8 54 42
Thrombin time (15.5–19.4 sec) NA 15.8 16.8 50.5 23.2 24.1 32.4 NA
Fibrinogen Clauss (1.8–4.2 g/L) NA 2.7 2.35 1.18 1.1 2.13 1.85 1.94
D-dimer (<500 µg/ml) 182 NA NA NA NA 1744 NA 2480
Laboratory values are only given for the first week of treatment, as thereafter the values are mainly influenced by renal replacement therapy (starting on day 4) and mass transfusions of 
blood and coagulation products (starting on day 5).
Abbreviations: INR, International Normalized Ratio; NA, not available.
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Infection Prevention and Control Measures
As soon as ANDV infection was suspected in patient 1, he was 
placed under contact and droplet precautions. These mea-
sures were stopped after the patient’s respiratory symptoms 
subsided. Being this patient’s only close contact, the wife was 
advised to seek medical attention in case of symptoms. The ED 
was informed of the need for contact and droplet precautions 
to prevent secondary cases. These precautions were started the 
second time the wife presented to the ED (day 1). Upon trans-
fer to the intensive care unit, infection control measures were 
Figure 1. Evolution of hemoglobin and thrombocyte values and corresponding transfusion needs for patient 2. Abbreviation: Hb, hemoglobin.
Figure 2. Chest radiography, day 3, and chest computed tomography scan with contrast enhancement, day 11, of patient 2.
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escalated to contact and airborne precautions in a negative pres-
sure room with anteroom. Daily ward rounds were performed 
by the infection prevention and control (IPC) team to ensure 
these measures were implemented correctly.
Local health authorities were informed of both cases, as 
required by Swiss law. The couple’s travel company was also 
notified, and a proMED message [1] was released.
A survey of all personnel exposed to these 2 patients before 
installation of isolation precautions found 35 contacts for 
each case. No unprotected exposure during an aerosol-cre-
ating procedure was identified. One cardiac surgeon received 
a blood-tinged splash of rinsing liquid close to his eye on day 
4. Serological follow-up was proposed, which he declined. He 
did not develop any symptoms suggestive of ANDV infection 
nor did any other healthcare worker involved.
Processing of blood samples was modified in order to prevent 
any exposure to aerosolized body fluids. Bedside tests were used 
wherever possible. Transport of blood samples within the hos-
pital and to the external laboratory was executed by porters; for 
road transport, tubes were placed in a safety container as required 
by law. Any blood analysis that required opening tubes after cen-
trifugation was performed in a safety cubicle. Type and screen 
testing can only be done with open tubes in our facility; hence, 
this analysis was omitted after risk evaluation from day 5 onward.
Waste and facility management are discussed in the 
Supplementary Materials. IPC measures were discontinued 
when follow-up RT-PCR tests indicated decreasing viral loads 
(VLs) after 10 weeks. Multiresistant P.  aeruginosa infection 
required continued contact precaution measures.
Virology
Molecular confirmation of ANDV was obtained by pan-Hanta-
virus RT-PCR [2] and subsequent sequencing of the amplicon 
for both patients. Phylogenetic analysis showed the strongest 
similarities with the ANDV isolate AH-1. Homology was later 
confirmed by complete genome analysis (manuscript in prepa-
ration). We monitored VL by an in-house quantitative real-time 
(qRT)-PCR method in EDTA whole blood and serum samples, 
respiratory specimens, and urine for up to 9 months, as shown 
in Figure 3. Detailed information on the qRT-PCR and serology 
can be found in the Supplementary Materials.
Discussion of the 2 Patients
Our 2 patients illustrate 3 major points: the clinical course of 
ANDV does not correlate with VL [3] but seems to be deter-
mined by host immunology [4]; IPC represents a substantial 
challenge in hemorrhagic fevers with potential human-to-hu-
man transmission; and ANDV appears to be yet another virus 
with prolonged viremia and shedding from sanctuary compart-
ments such as semen.
While the clinical course in patient 1 was of moderate severity, 
patient 2, despite lower viremia, experienced severe hantavirus 
cardiopulmonary syndrome (HCPS). We assume her severe 
lung damage to be multifactorial, including host immunology, 
viral pathology, hemorrhage, sepsis, and ventilation damage. 
Lung biopsy was not performed. The prolonged cardiorespira-
tory failure led us to suspect bacterial and later fungal super-
infection. In retrospect, administration of broad-spectrum 
antibiotics in the initial phase would not have been necessary 
and favored appearance of multiresistant P.  aeruginosa. Our 
second patient was treated with ribavirin in view of encourag-
ing results in an animal model [5], despite concerns about side 
effects and lack of effectiveness.
The prolonged detection of viral RNA in different body com-
partments (respiratory secretions, whole blood, and semen) 
was unexpected. While whole blood samples were last positive 
on day 74 in patient 2 and on day 151 in patient 1, monitoring 
of semen in patient 1 was still ongoing at the time this manu-
script was submitted. Despite this prolonged replication in vari-
ous compartments, to our knowledge, clinical relapses have not 
been described and did not occur in our patients either.
The incubation periods for our patients were 5 to 34  days 
and 25 to 54 days. The interval between presentations of the 2 
patients was 20 days, coinciding with the reported median for 
cases of person-to-person transmission. Our couple reported 
having sex only with condoms, leaving “deep kissing” as a pos-
sible route of transmission [6]. However, exposure to a common 
source is more frequent, and the incubation period for patient 2 
is also compatible with such a scenario.
THE PATIENTS PUT IN CONTEXT—LITERATURE  
REVIEW
ANDV, a New World species of the genus Orthohantavirus, 
family Hantaviridae, belongs to the order of Bunyavirales [7]. 
It was first isolated in 1995 and is mainly found in Argentina 
and Chile, where seroprevalences vary from 0.5% to 6% [8]. 
HCPS was first described in 1993 in a patient with Sin Nombre 
virus infection in the United States [9, 10]. About 4000 HCPS 
cases have since been reported in South America [11]. In 2016, 
a local outbreak of ANDV caused 7 fatal cases in the region of 
Araucania, Chile [12]. Our patients had travelled that region 
during the last 3 weeks of their journey. Infection with ANDV 
has not been previously reported in Europe.
Transmission from its host, the long-tailed pygmy rice rat 
(Oligoryzomys longicaudatus), occurs through inhalation of 
dried excreta or direct contact [13]. To date, ANDV is the only 
hantavirus known to be transmitted from person to person, a 
characteristic first described in 1995 [14]. The exact route of 
transmission remains unclear. About one third of the cases 
occur in clusters, with a median of 19.5 days between symptom 
onset in index and secondary cases (range, 4–30 days) [6].
ANDV has been detected in peripheral blood cells up to 
15 days before (median, 11 days) and 35 days after symptom 
onset [6]. Viable ANDV was also found in urine of patients 
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with HCPS [15]; furthermore, viral RNA was shown in gin-
gival crevicular fluid and in saliva [16]. In a 4-week serologi-
cal follow-up of 476 household contacts of 76 HCPS patients, 
the major risk factor for acquiring ANDV was being a sex 
partner, with 17.6% infected vs 1.2% of other household con-
tacts (relative risk [RR], 14.9; 95% confidence interval [CI], 
5.2–43.5), as was deep kissing (RR, 17.1; 95% CI, 4.7–62.5) 
and sharing the same bed (RR, 12.5; 95% CI, 4.0–38.5) [6]. In 
another study, patients with fatal outcome were more likely 
to have caused secondary cases (41% vs 4%; P = .005) [17].
Reports of 2 ANDV outbreaks [18, 19] provide strong epi-
demiologic evidence for the virus’s potential for nosocomial 
transmission, one involving 18 individuals, 5 of whom were 
physicians, with suspected transmission chains of up to 4 
patients [18]. However, common exposure to rodent excreta 
might have been involved in some of the links. In contrast, 
Figure 3. Course of Andes hantavirus RNA and anti-Andes hantavirus immunoglobulin (Ig) G/IgM antibodies for patient 1 (A) and patient 2 (B). RNA levels were assessed 
using in-house quantitative real-time polymerase chain reaction (qRT-PCR); measurements where a pronounced qRT-PCR inhibition was observed are marked with as aster-
isk (*). Serological parameters were assessed qualitatively by IgM/IgG immunoblot assay (IBA) (Euroline Hantavirus profile global, Euroimmun) and semiquantitatively by 
enzyme-linked immunosorbent assay (ELISA; Hantavirus Profile global, Euroimmun) by determining test-sample-to-calibrator ratio with a ratio of ≥1.1 rated positive (border-
line ratio ≥0.8 to <1.1); for IgG, a ratio of 8 corresponds to 260 RU/mL, a ratio of 5 to 160 RU/mL, and a ratio of 0.8 to 16 RU/mL. Comment on patient 1: viral load on day 1 
was from a serum sample, and from day 4 onward from EDTA blood. On day 3, high Andes hantavirus (ANDV) viral load (8.07 × 105 GE/mL) in whole blood contrasted with a 
substantially lower load in serum (2.82 × 104 GE/ml) from the same day. Comment on patient 2: She tested negative for ANDV by RT-PCR in serum and for specific antibodies 
1 week before onset of symptoms. Two days after admission, a high virus load was found in whole blood (1.07 × 106 GE/mL) and Hantavirus-specific IgM (ratio 2.5) and IgG 
antibodies (ratio 8.73) were detected by ELISA and IBA.
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seroprevalences of healthcare workers exposed to respiratory 
secretions and blood of HCPS patients were not higher than in 
their community but lower than in household contacts [20–22]. 
This was noted despite poor compliance with IPC practices in 
some of the involved hospitals.
Clinical manifestations of ANDV infection range from 
unspecific febrile illness to its most severe form, HCPS. After 
an incubation period of 2 to 3 weeks (range, 7 to 39 days) [23], 
patients present with nonspecific prodromal symptoms over 
2 to 8 days. Typically, respiratory symptoms and infiltrates on 
chest X-ray are absent in the beginning. Blood count may reveal 
thrombocytopenia, hemoconcentration, leucocytosis with left 
shift, and atypical lymphocytes [13, 24]. The cardiopulmonary 
phase begins abruptly, with cough, dyspnea, and precipitous 
hemodynamic instability due to cardiogenic shock and pulmo-
nary edema. Capillary leak leads to hypovolemia, which may 
further impair cardiac and renal function. Hemorrhagic com-
plications may occur [13], although severe disseminated intra-
vascular coagulation is uncommon. In this phase, the disease 
can rapidly progress to multiorgan failure, and death may occur 
within 24 hours [25]. Disease pathology, which is characterized 
by microvascular leakage, is mainly attributed to host immune 
response, illustrated by the fact that infection of endothelial 
cells does not lead to cytopathology [26, 27]. Viral load does 
not appear to predict the severity of clinical presentation [3]. 
The cardiopulmonary phase usually lasts up to 7  days and is 
followed by a diuretic phase with resolution of the pulmonary 
edema. Convalescence may require several months.
Mortality in patients with HCPS due to ANDV is 20% to 40% 
[8, 28]. In survivors, antibody titers remain elevated for several 
years [29]. Reinfections have not been described to date [8].
Diagnosis is confirmed by RT-PCR from whole blood or by 
serology, either with presence of specific IgM antibodies or an 
at least 4-fold increase in IgG titers [30]. In early stages of the 
disease, RT-PCR, with a sensitivity of 100% and a specificity of 
94% [31], is preferred over serology, which is typically negative 
in the prodromal phase. IgM can persist for up to 1  month. 
Whole blood yields higher levels of viral RNA than serum sam-
ples. A study found that ANDV RNA was still detected in leu-
cocytes of 12 of 14 patients 84 days after presentation, while the 
ANDV RNA detected in plasma samples decreased rapidly over 
the first 7 days [32].
To date, there is no specific treatment or a vaccine against 
ANDV. Organ supportive therapy is the mainstay of treatment. 
Patients should be transferred to a tertiary intensive care unit 
immediately upon suspicion of ANDV infection, as ECMO 
support might be required [8]. ECMO is ideally placed before 
hemodynamic instability and major coagulopathy develop, 
according to a study comparing outcomes of 51 patients with 
Sin Nombre virus infection [33].
Ribavirin was shown to reduce mortality in patients with Old 
World hantavirus infection causing renal syndrome [34]. An in 
vitro study in ANDV-infected human endothelial cells demon-
strated that ribavirin is highly effective in preventing viral 
replication but not efficient in completely suppressing the over-
whelming cytokine production [35]. However, a metaanalysis 
[36] of 2 clinical studies, limited by their small case numbers, 
concluded that there was no treatment benefit in New World 
hantavirus infections.
Treatment with corticosteroids showed no significant effect 
on mortality [28, 32]. A recently published nonrandomized trial 
on 29 ANDV cases showed a trend toward reduced mortality in 
patients treated with plasma from HCPS survivors collected at 
least 6 months after their recovery [37].
Literature on IPC measures for ANDV is sparse. This poses 
a substantial challenge to clinical management. The Ministry of 
Health of Argentina [8] suggests standard hygiene and drop-
let precautions as well as treating the patient in a single room. 
During aerosol-generating procedures, however, healthcare 
workers are advised to wear high-efficiency respirator masks 
and ocular protection. We opted for a conservative approach in 
view of the nosocomial transmissions described in the literature 
and the severe course of patient 2. IPC measures were initially 
reiterated to the multiple involved teams on a daily basis. Risk 
perception varied among involved personnel and corresponded 
to different levels of anxiety, but this did not lead to refusal to 
care for the patient.
According to the Centers for Disease Control and Prevention 
[38], handling of human samples with ANDV infection 
requires biosafety level (BSL) 2, whereas treating cell cultures 
and infected rodents’ tissues requires BSL 3 precautions.
As an enveloped virus, ANDV should be vulnerable to com-
mon disinfectants. Direct evidence for ANDV is lacking, so 
we based our decisions on studies of Old World hantaviruses, 
which showed inactivation by commonly used disinfectants 
[39, 40].
CONCLUSIONS
The report of these first 2 ANDV patients in Switzerland illus-
trates the variable clinical course of the disease and highlights 
the multiple levels of awareness and decision-making required 
in the recognition and management of unexpected, highly 
pathogenic, and potentially nosocomially transmissible agents. 
Treatment of returning sick travellers requires not only ruling 
out common febrile diseases but also awareness of the current 
epidemiology in the regions visited. The triad of inexplicable 
severe exhaustion, fever, and thrombocytopenia in an appropri-
ate epidemiological context should alert clinicians to the possi-
bility of a viral hemorrhagic fever. In ANDV infection, initial 
clinical findings are unspecific and rarely provide clues as to 
which patient will develop HCPS. Therefore, a low threshold 
for clinical suspicion of the entity and rapid transfer to a ter-
tiary care center with ECMO and transfusion facilities are key 
to improving prognosis in severe HCPS.
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The lack of clear knowledge on the exact transmission mode 
and the duration of infectivity posed substantial challenges for 
our IPC team. These uncertainties are reflected in IPC mea-
sures that consist of contact and different aspects of respiratory 
precautions, which does not fit any standard IPC approach. In 
retrospect, excluding laboratory procedures for the sole reason 
that they involved open tubes was overly cautious and might 
have unduly hampered clinical management of the patient. For 
the hospital as a whole, the management of these 2 patients has 
greatly improved overall knowledge and awareness of manag-
ing critically ill patients with uncommon infections that require 
enhanced precaution measures.
SUPPLEMENTARY DATA 
Supplementary materials are available at Clinical Infectious Diseases. 
Consisting of data provided by the author to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the author, so 
questions or comments should be addressed to the author. 
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